Lonitoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor. Lonitoclax has comparable anti-tumor efficacy to Venetoclax.

LON 954, a tremorogenic agent, is a reversible monoamine oxidase (MAO) inhibitor. LON 954 inhibits MAO activity in various tissue preparations.

LO-4-25 is a covalent degrader targeting the androgen receptor (AR) and its truncated variant AR-V7. LO-4-25 covalently binds to the E3 ubiquitin ligase CUL4 DCAF16, promoting the ubiquitination of AR and AR-V7, which subsequently are recognized and degraded by the proteasome, reducing the protein levels of AR and AR-V7 in cells. LO-4-25 is promising for research of androgen-independent prostate cancers.

LNK4-S is a drug-linker conjugate, that can be used for synthesis of ADC molecule M-VA-EXA and F-VA-EXA.

LIB3S0280 is a potent TBK1 inhibitor with an IC50 value of 493.9 nM. LIB3S0280 can inhibit TBK1 downstream signaling by decreasing the phosphorylation of IκBα and AKT. LIB3S0280 leads to G2/M arrest and induces apoptosis in pancreatic cancer cells. LIB3S0280 shows significant inhibition against pancreatic cancer cell lines that highly express TBK1 with IC50 values of 6.64-10.98 μM at 96 h. LIB3S0280 has the potential for pancreatic ductal adenocarcinoma (PDAC) research.

LH168 is a potent and selective chemical probe for WDR5, with a SPR Kd value of 13 nM.

LH10 is a fexaramine-based agonist for FXR with an EC50 of 0.14 μM. LH10 exhibits liver protection efficacy, ameliorates the alpha naphthylisothiocyanate (ANIT)-induced cholestasis, APAP. Benzoyl coenzyme A (sodium) is A derivative of Coenzyme A (CoA) in which the mercaptan group of CoA binds to the benzoyl group. Benzoyl coenzyme A (sodium) is involved in the catalytic reaction as a substrate for the acyl transfer reaction. Benzoyl coenzyme A (sodium) is a versatile metabolic intermediate that can be used to reveal substrate specificity of enzymes, metabolic regulation, and drug metabolism.

Leucomycin A4 is a macrolide antibiotic that can be extracted from S. kitasatoensis. Leucomycin A4 inhibits a variety of bacteria, including S. aureus, B. subtilis, C. diphtheriae, N. gonorrhoeae, and H. influenzae (MICs = 0.15, 1.25, 0.15, 0.6, and 0.15 µg/ml, respectively).

Leucinostatin H is a polypeptide antibiotic discovered in Paecilomyces marquandii, characterized by a tertiary amine-oxide terminal group. Leucinostatin H exhibits inhibitory activity against Gram-positive bacteria, such as Bacillus subtilis, B. cereus, and Staphylococcus aureus (MIC 10-100 μg/mL). Leucinostatin H holds potential for research in anti-infective and plant disease control applications.

Lenalidomide-hex-5-ynoic acid is a conjugate of E3 ligase ligand and linker, and can be used to synthesize PROTACs, such as PROTAC cGAS degrader-1.

Lenalidomide-Glycolic acid is a E3 Ligase Ligand-Linker Conjugate for PROTAC-class FLT3 degrader LWY713.

Lenalidomide-C13-piperazine-Boc is a conjugate of the E3 ligase ligand and the linker, that can be used for synthesis of PROTAC degrader NC-R17.

Lenalidomide-amide-pimelic acid is an E3 ligase ligand-linker conjugate that incorporates the Lenalidomide based CRBN ligand and Linker. Lenalidomide-amide-pimelic acid can be used for synthesis of PROTAC MNK1 degrader-1.

Lenalidomide-5-Br-amide-C2-Br is an E3 ligase ligand-linker conjugate. Lenalidomide-5-Br-amide-C2-Br can be used to synthesize PROTAC DDR1 degrader-1. Palbociclib is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively.

LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR (IC50 values are 71.6 and 8.9 nM, respectively). LC-SF-14 inhibits FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation. LC-SF-14 inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). LC-SF-14 has antitumor activity in the SNU-16 xenograft mouse model. LC-SF-14 can be used in FGFR2-driven gastric cancer research.

LC3B recruiter 2 (34R) is an LC3B recruiter and a component of the autophagy-lysosome pathway degradation system (ATTEC, Autophagy-Tethering Compounds), which directly binds to LC3B. LC3B recruiter 2 binds to CDK9 inhibitor SNS-032 through a linker, forming an ATTEC that targets the degradation of the CDK9 and Cyclin T1 complex (with inhibitory effects on both). Therefore, LC3B recruiter 2 exerts activity through the LC3B-dependent autophagy-lysosome pathway, interfering with the cell cycle of cancer cells, thus exhibiting antitumor activity.

LC3B recruiter 1 (compound 33R) is an LC3B recruiter fragment. LC3B recruiter 1 directly interacts with LC3B with a KD value of 2.87 µM.

LAU-0901, a PAF receptor antagonist, possesses highly neuroprotective activity. LAU-0901 inhibits apoptosis.

LA-CB1 is an Abemaciclib, which is an bivalent AR (Androgen Receptor) degrader. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa.

L321-NH-C3-PEG3-C1-NH2 (CRBN ligand L321) is an E3 Ligase Ligand-Linker Conjugate for BRD4 PROTAC L134.

4-Methylphenoxyacetic acid-Oxindole-CF3 is the E3 ligase ligand part of L134.

KYLO-0603 is an orally active, selective THR-β agonist (EC50: 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research.

KU13 is an inhibitor of nontuberculous mycobacteria (NTM). The minimum inhibitory concentrations (MIC) of KU13 against Mycobacterium and E. coli are 0.032-8 μg/mL and 2 μg/mL, respectively. KU13 can be used for research in the field of anti-infection .

KRO-105714 is the antagonist for sphingosine phosphocholine receptor (SPC Receptor) and sphingosine-1-phosphate receptor 1 (S1P1 Receptor) (IC50=79.2 nM). KRO-105714 inhibits SPC-induced proliferation of NIH3T3 (IC50=5.6 nM), inhibits SPC-induced cell migration (IC50=0.59 μM) and tube formation in HUVECs. KRO-105714 inhibits SPC-induced generation of IL-4 and IL-5, exhibits anti-inflammtory efficacy in mouse atopic dermatitis models.

KK181N1 is a potent inhibitor of karrikin (KAR) receptor KAI2. KK181N1 binds to the catalytic pockets of KAI2 in a non-covalent binding manner. KK181N1 selectively depress the KAR-induced phenotypes in Arabidopsis.

KF-52 is a phosphofructokinase-1 (PFK1) inhibitor, with an IC50 of 2.1 μM. KF-52 significantly increases the OCR/ECAR (OCR: oxygen consumption rate; ECAR: extracellular acidification rate) ratio.

Ketoprofen (RP-19583) sodium is a non-steroidal anti-inflammatory agent. Ketoprofen sodium can inhibit the activity of Cyclooxygenase with IC50 values of 2 nM (COX-1) and 26 nM (COX-2). Ketoprofen is potential in the research of inflammation, immunology, and metabolic disease such as obesity.

KCC2 potentiators-1 (Compound 2) is a Potassium chloride cotransporter-2 (KCC2) potentiator. KCC2 potentiators-1 is promising for research of neurological disorder.

Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis.

Kalafungin is an antibiotic, antimicrobial agent and a β-lactamase inhibitor from marine Streptomyces, with IC50 of 225.37 μM. Kalafungin destroys cell membranes. Kalafungin shows inhibitory activities against a variety of pathogenic fungi, yeasts, protozoa, gram-positive bacteria (such as S. aureus ATCC 33591 and S. aureus ATCC 23591), and, to a lesser extent, gram-negative bacteria.